X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
Details:
This financing will enable MinervaX to progress its novel GBS vaccine GBS-NN/NN2, towards Phase III clinical trials in 2024. The Company is currently progressing two Phase II clinical trials in 470 pregnant persons across Denmark, United Kingdom, Uganda and South Africa.
Lead Product(s): GBS-NN,Aluminum
Therapeutic Area: Infections and Infectious Diseases Product Name: GBS-NN/NN2
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: EQT Life Sciences
Deal Size: $56.8 million Upfront Cash: Undisclosed
Deal Type: Financing October 11, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
